Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Miralogx LLC is currently navigating 5 pending office actions within the Biotechnology & Pharmaceuticals technology area. The portfolio is notably fragmented, as these actions are spread across 5 distinct art units and 5 distinct examiners. This one-to-one ratio between actions, examiners, and art units suggests that the company's biotechnology filings cover a diverse range of sub-specialties.
Each examiner, including the busiest examiner SCHMIDT, IZABELA MARIA, is responsible for only 1 pending action. This distribution means that the company's current prosecution strategy must be uniquely tailored to 5 different sets of examiner expectations. With 5 distinct art units involved, the company must also address the specific technical guidelines of five separate examination groups. This lack of consolidation prevents the company from applying a single examiner's feedback across multiple pending matters in the pharmaceutical space. The prosecution team must manage 5 independent tracks simultaneously.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (40%) |
| §102 only | 1 (20%) |
| §112 only | 1 (20%) |
| Multi-statute (no §101) | 1 (20%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHMIDT, IZABELA MARIA | 1 | 65.7% | +42.7% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| LEESER, ERICH A | 1 | 81.9% | +13.3% |
| CORNET, JEAN P | 1 | 41.9% | +47.2% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18755178 | Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods | LEESER, ERICH A | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19034034 | Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders | SCHMIDT, IZABELA MARIA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19034034 | Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders | SCHMIDT, IZABELA MARIA | — |
| 18832143 | Anticancer Compounds, Pharmaceutical Compositions, and Methods of Treating Cancers | RAO, SAVITHA M | — |
| 18755178 | Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods | LEESER, ERICH A | — |
| 18721001 | Anti-inflammatory Compounds, Pharmaceutical Compositions, and Treatment Methods | CORNET, JEAN P | — |
| 18673060 | Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders | VALLE, ERNESTO | — |
| Art Unit | Apps |
|---|---|
| 1621 | 1 |
| 1691 | 1 |
| 1622 | 1 |
| 1628 | 1 |
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19034034 | Synthetic Cannabigerol Quinone Analogs and Pharmaceutical Compositions Containing Same for Treating Neurological Disorders | SCHMIDT, IZABELA MARIA | 1621 | §103§112 | Non-Final OA | — | Pending | Jan 22, 2025 |
| 18832143 | Anticancer Compounds, Pharmaceutical Compositions, and Methods of Treating Cancers | RAO, SAVITHA M | 1691 | §102Other | Non-Final OA | — | Pending | Jul 23, 2024 |
| 18755178 | Synthetic Cannabinoid Compounds, Pharmaceutical Compositions, and Treatment Methods | LEESER, ERICH A | 1622 | §103 | Non-Final OA | — | Pending | Jun 26, 2024 |
| 18721001 | Anti-inflammatory Compounds, Pharmaceutical Compositions, and Treatment Methods | CORNET, JEAN P | 1628 | §112 | Non-Final OA | — | Pending | Jun 17, 2024 |
| 18673060 | Anxiolytic Compounds, Pharmaceutical Compositions, and Methods of Treating Anxiety and Other Disorders | VALLE, ERNESTO | 1623 | §103 | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialMiralogx LLC has 5 pending office actions as of October 2026, spread across 5 art units and 5 examiners.
Izabela Maria Schmidt has the most, with 1 of Miralogx LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
